Thompson LLP advised NIRx Medical Technologies, a global leader in functional Near-Infrared Spectroscopy (fNIRS) solutions, in a strategic transaction forming a new group in combination with Artinis Medical Systems. The combination was financed by private equity firm Gilde Healthcare. The newly established group is poised to accelerate innovation and drive commercial growth in the neuroimaging sector.
The transaction involved a series of parallel deals that unite two pioneering companies in fNIRS technology with the backing of a leading healthcare-focused private equity investor.
“With fNIRS entering a new phase of commercial maturity, Gilde Healthcare recognized the opportunity to bring together two of the field’s most influential players,” said Ben Thompson. “This partnership not only positions the group for significant global growth but also advances the broader mission of making brain imaging technology more accessible to researchers worldwide.”
fNIRS is a differentiated neuroimaging technology that offers unique advantages over traditional methods like fMRI and EEG. With growing applications in areas such as neurodegenerative diseases, mental health, stroke rehabilitation, and developmental neuroscience, fNIRS is reshaping how researchers study and understand the human brain.
The Thompson LLP deal team included Ben Thompson, Christopher Condlin, Michael Orenstein, Dustin Barzell, Karin Weiner, Robert Moorman, and Bolu Odubayo.